Skip to content
value.today
Total raised
$34 M
2 rounds on record
Latest round
$19 M
Jun 2026
First round on record
Apr 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Rejuvenate Bio Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$19 MNo. 2$10 to $50 million

Rejuvenate Bio Inc: Raise no. 2, Jun 2026

Investors in this round

35 investors had bought by the notice of Jun 18, 2026: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $27 M offered; $8 M still to sell
Smallest investment taken
$20,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Oliver · Executive Officer, Director
  • Noah Davidsohn · Executive Officer, Director
  • David Zhu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes conversion of convertibles (notes, SAFEs and warrants) in the amount of $13,049,354.51”

Signed by John Park, General Counsel. Source: SEC Form D, newest notice filed Jun 18, 2026. Read the notice at the SEC.

equitySEC
Apr 2021$15 MNo. 1$10 to $50 million

Rejuvenate Bio Inc: Raise no. 1, Apr 2021

Investors in this round

22 investors had bought by the notice of Apr 27, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Oliver · Executive Officer, Director
  • Noah Davidsohn · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Park, Attorney in Fact. Source: SEC Form D, newest notice filed Apr 27, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Rejuvenate Bio Inc reported revenue of $2.54 million for its most recent fiscal year (filed Aug 2026), up from $0 the year before.

    SEC Form C/A · Aug 2026

  • The direct cost of what it sold was $2.25 million, so 11% of its revenue was left after those costs.

    SEC Form C/A · Aug 2026

  • Net loss for the same year: $3.16 million.

    SEC Form C/A · Aug 2026

  • Rejuvenate Bio Inc chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of Rejuvenate Bio Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 35 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Rejuvenate Bio Inc
NameRoleNamed in
Daniel OliverExecutive officerJun 2026
Noah DavidsohnExecutive officerJun 2026
Daniel OliverDirectorJun 2026
David ZhuDirectorJun 2026
Noah DavidsohnDirectorJun 2026